Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 15/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | ITGAV | P06756 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7417558 | 0.95 | ITGB3 (0.49) | ITGB3ITGA2BPPARGITGAVCHRM2 | |
| SCHEMBL7418575 | 0.89 | ITGB3 (0.55) | ITGB3ITGA2BITGAV | |
| SCHEMBL7412563 | 0.88 | AVPR1B (0.51) | ITGB3ITGA2B | |
| SCHEMBL7412450 | 0.88 | ITGB3 (0.69) | ITGB3ITGA2BPPARGITGAVCHRM2 | |
| SCHEMBL7411712 | 0.87 | TDP1 (0.59) | ITGB3ITGA2BMMP2MMP9TDP1 | |
| SCHEMBL7423110 | 0.87 | ITGB3 (0.48) | ITGB3ITGA2BPPARGITGAVMMP2 | |
| SCHEMBL7418686 | 0.86 | ITGB1 (0.51) | ITGB3ITGA2BPPARGITGAV | |
| SCHEMBL7416684 | 0.86 | ITGB3 (0.52) | ITGB3ITGA2BITGAV | |
| SCHEMBL7463784 | 0.86 | ITGB3 (0.48) | ITGB3ITGA2BITGAV | |
| SCHEMBL7420817 | 0.86 | ITGB3 (0.56) | ITGB3ITGA2BITGAVCHRM2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6344484-B1 | TREATMENT OF TUMOR GROWTH, METASTASIS, OSTEOPOROSIS, RESTENOSIS, INFLAMMATION, MACULAR DEGENERATION, DIABETIC RETINOPATHY, AND RHEUMATOID ARTHRITIS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-05 | — | — | US | claimed |
| EP-1159262-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2000047552-A1 | TYROSINE ALKOXYGUANIDINES AS INTEGRIN INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |